The Drying Pipeline

Both AstraZeneca and Novartis announced that drugs they had for depression and hypertension that were in the late stages of development have failed, reports Bloomberg, adding that AstraZeneca's drugs turned out to be disappointing while Novartis's tests on Tekturna were halted due to safety concerns. Further, Sanofi's multiple sclerosis drug, Aubagio, has not performed better than an older therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.